Top Back to top

Outcomes of Allogeneic HCT in patients with Hodgkin Lymphoma in the era of Checkpoint Inhibitors: A joint CIBMTR and EBMT analysis.

Lymphoma Working Party (LWP)
Study number:
Short title:
Allo HSCT For HL in the era of Checkpoint Inhibitors
Primary objective:
Key inclusion criteria:
Principal investigator:
Miguel-Angel Perales
EBMT Study coordinator:
Hervé Finel
Study coordinator email: